Reporting owner · CIK 0002042077

Chernett Jorey

SEC Form 4 history for the last 180 days across 4 companies, 26 transactions and 11 filings.

10%Neuronetics, Inc.
Open-market transaction mix58% buys15 buys · 11 sales

Period: Last 180 days

Trade dates in this period: Jun 4, 2026 – Nov 13, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings11Form 4 records
Buying$1.02M15 purchases
Selling$16.7M11 sales
Net value−$15.7MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Chernett Jorey transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
STIMNeuronetics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$2.52MView disclosure →
STIMNeuronetics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$1.01MView disclosure →
STIMNeuronetics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$140kView disclosure →
STIMNeuronetics, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$79.6kView disclosure →
STIMNeuronetics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$214kView disclosure →
STIMNeuronetics, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$599kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$237kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$509kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
Derivative securitySEC filing ↗
$1.11kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$373kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Derivative securitySEC filing ↗
$1.11kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$37.3kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$54.0kView disclosure →
XGNEXAGEN INC.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$69.2kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Derivative securitySEC filing ↗
$4.69kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Derivative securitySEC filing ↗
$4.02kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Derivative securitySEC filing ↗
$2.00kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Derivative securitySEC filing ↗
$750View disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$176kView disclosure →
STLNStarling Oncology, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$11.4MView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Neuronetics, Inc. on Nov 13, 2026 valued at $2,515,108.65.

Review SEC filing
Latest buy

The insider reported a buy at Starling Oncology, Inc. on Nov 11, 2026 valued at $1,112.80.

Review SEC filing

Monthly open-market activity

Last 4 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Jun 202610$57,000$0+$57,000
Aug 202622$122,720$945+$121,775
Oct 202610$104,440$0+$104,440
Nov 2026119$733,776$16,669,841.05−$15,936,065.05

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$680k
Median P/S size$73.8k
Direct26
Indirect0
Nov 13, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Average return−45%Across 1 open-market buy
Median return−45%Half the buys outperformed this
How it's computed

For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.

  • Scope is the last 180 days shown in this profile. Earlier purchases are not included.
  • Only buys with a resolved price context are counted.
  • Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

7 observations · Aug 14, 2026 – Nov 13, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 13, 20267,325,577 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 14, 202610,602,988Aug 17, 2026View transaction
Nov 6, 202610,370,184Nov 13, 2026View transaction
Nov 9, 202610,266,225Nov 13, 2026View transaction
Nov 9, 202610,306,225Nov 13, 2026View transaction
Nov 11, 202610,219,468Nov 13, 2026View transaction
Nov 12, 20269,512,628Nov 13, 2026View transaction
Nov 13, 20267,325,577Nov 13, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Chernett Jorey Insider Activity FAQ

SEC Form 4 context

Who is Chernett Jorey?

Chernett Jorey is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002042077.

Which companies has Chernett Jorey reported transactions for?

Neuronetics, Inc., EXAGEN INC., Starling Oncology, Inc., Oncology Institute, Inc., Airsculpt Technologies, Inc.

When was Chernett Jorey's latest insider buy?

The insider reported a buy at Starling Oncology, Inc. on Nov 11, 2026 valued at $1,112.80.

When was Chernett Jorey's latest insider sale?

The insider reported a sale at Neuronetics, Inc. on Nov 13, 2026 valued at $2,515,108.65.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.